Immune Regulation of COVID-19 Infection in Cancer and Autoimmunity

癌症和自身免疫中 COVID-19 感染的免疫调节

基本信息

批准号：
10680633
负责人：
MADHAV V DHODAPKAR
金额：
$ 35.92万
依托单位：
EMORY UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2020
资助国家：
美国
起止时间：
2020-09-30 至 2024-11-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10680633
关键词：
2019-nCoV African American Age Autoimmunity B lymphoid malignancy B-Cell Lymphomas B-Lymphocytes Blood Bone Marrow COVID-19 COVID-19 morbidity COVID-19 mortality COVID-19 pandemic COVID-19 patient COVID-19 risk COVID-19 vaccination COVID-19 vaccine Cancer Patient Clinical Data Data Development Disease Disease Progression Health Hematologic Neoplasms Immune Immune checkpoint inhibitor Immune response Immune system Immunity Immunologic Memory Immunologics Immunology Immunosuppression Immunotherapy Impairment Individual Inflammation Inflammatory Response Lead Malignant Neoplasms Malignant neoplasm of lung Morbidity - disease rate Multiple Myeloma Natural Immunity Non-Small-Cell Lung Carcinoma Outcome Paresis Pathology Patient Care Patients Plasma Cell Neoplasm Plasma Cells Population Recording of previous events Regulation Research Personnel Risk SARS-CoV-2 exposure SARS-CoV-2 immunity SARS-CoV-2 infection Serology T cell response Vaccines Viral Viral Cancer Virus Virus Diseases adaptive immunity antiviral immunity cohort comorbidity coronavirus disease experience global health high risk hypogammaglobulinemia immune checkpoint immune checkpoint blockade immune-related adverse events immunopathology immunoregulation insight mortality multidisciplinary pathogen post SARS-CoV-2 infection research clinical testing response severe COVID-19 standard care standard of care targeted treatment tumor tumor immunology

项目摘要

Project 3: Title: Regulation of SARS CoV-2 immunity in cancer patients Project leaders: Madhav Dhodapkar and Rafi Ahmed Project Summary: Patients with cancer are at increased risk of morbidity and mortality relating to SARS CoV-2 infection. However the immunologic underpinnings of wide variance in COVID-19 disease course in cancer patients are unknown. In addition to underlying cancer associated immune paresis, therapies used to treat cancer can further increase the risk of COVID related pathology. In this proposal, we have assembled a multidisciplinary team to tackle these questions. These studies build directly on our prior expertise and experience in studying immunity in viral infections and cancer. We will focus in particular on patients with B/plasma cell tumors treated with B/plasma cell depleting therapies and those with lung cancer treated with immune checkpoint blockade. Studies in aim 1 will evaluate the impact of therapy-related immune paresis on protective immunity to SARS CoV-2 and viral clearance in patients with B/plasma cell malignancies. Studies in aim 2 will evaluate anti-viral immunity and immunopathology in patients with lung cancer receiving immune checkpoint blockade. Studies in aim 3 will evaluate immunologic responses to SARS CoV-2 vaccines in patients with B/plasma cell tumors and lung cancer once they are approved and administered as a part of standard care. These studies will not only provide basic insights into protective immunity to SARS CoV-2, but also provide essential information for optimal care of these patients in the face of concurrent SARS CoV-2 infection.

项目3：标题：癌症患者中SARS COV-2免疫的调节项目负责人：Madhav Dhodapkar和Rafi Ahmed 项目摘要：癌症患者与SARS COV-2感染有关的发病率和死亡率的风险增加。然而患者未知。除了基本的癌症相关免疫减轻外，还习惯了治疗癌症可以进一步增加相关病理的风险。在这个建议中，我们有组建了一个多学科团队来解决这些问题。这些研究直接基于我们的先前研究病毒感染和癌症免疫的专业知识和经验。我们将集中精力特别针对B/浆细胞肿瘤的患者B/浆细胞耗尽疗法和患有免疫检查点封锁治疗的肺癌的人。 AIM 1的研究将评估与治疗相关的免疫减轻对SARS COV-2和病毒清除的保护性免疫的影响 B/浆细胞恶性肿瘤的患者。 AIM 2的研究将评估抗病毒免疫力和肺癌患者的免疫病理学接受免疫检查点阻滞。瞄准中的研究 3将评估B/浆细胞肿瘤患者中SARS COV-2疫苗的免疫学反应肺癌一旦获得批准并作为标准护理的一部分进行管理。这些研究不仅将提供对SARS COV-2保护性免疫的基本见解，而且还提供了必不可少的面对并发的SARS COV-2感染，这些患者的最佳护理信息。